
Please try another search
Vanta Bioscience Limited, together with its subsidiaries, operates as a preclinical contract research organization in India. It offers a range of services in method development, validation, impurity profiling, impurity isolation, characterization, certification and evaluation, mammalian and genetic toxicology, drug metabolism, pharmacokinetics, and bio-analysis during the preclinical stage of drug development. The company also provides testing services for agrochemicals and chemicals, such as physico-chemical testing; sub-acute, sub-chronic, and chronic; toxicokinetics assessment, CoA and dose formulation analysis, 5 batch analysis, and studies on behavior in water, soil and air, bioaccumulation, as well as acute 6 pack, carcinogenicity, genetic toxicity, DART, eco-toxicity, and alternative to animal studies. In addition, it offers diet formulation services, which include starter material processing, proximate and composition analysis, diet balancing and formulation, irradiation, and packaging and labeling; and batch release pharmacopoeia tests, such as pyrogen testing, stability studies, and abnormal toxicity and impurity profiling. Further, the company provides services to medical device industry including cytotoxicity, intracutaneous/mucous membrane irritation, dermal sensitization, mutagenicity assays, acute systemic toxicity, and implantation tests. Additionally, it is involved in the provision of risk assessment services to evaluate the active pharmaceutical ingredients, excipients, extractable, leachables, and pharmaceutical impurities; and expert services to determine health based exposure limits for permitted daily exposure or allowable daily exposure, including occupational exposure limits. The company offers its services to pharmaceutical, biotech, cosmetics, food supplements, feed additives, agri-food, and food supplements industries. Vanta Bioscience Limited was incorporated in 2016 and is based in Secunderabad, India.
Name | Age | Since | Title |
---|---|---|---|
Dopesh Raja Mulakala | 39 | 2016 | MD & Director |
Kathyayani Gonuguntla | 69 | 2017 | Independent Director |
Padmanabhuni Venkata Appaji | 75 | 2017 | Independent Director |
Kartini Binti Abdul Manaf | 62 | 2023 | Independent Non-Executive Director |
Yogeswara Rao Danda | 69 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review